How to Appeal a Zepbound Prior-Authorization Denial

By the PriorAuthAppeal editorial team · Sources cited · Independent of Eli Lilly

Last reviewed 2026-05-06

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity, and received a second FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity — making it the first weight-loss medication ever approved to treat a specific obesity-related disease. If your insurer just denied your prior authorization, this guide explains exactly why that likely happened, what the law says about your right to appeal, and how to build the strongest possible case for reconsideration.

At a glance

• Generic name: tirzepatide (2.5 mg titrated up to 15 mg weekly subcutaneous injection)
• FDA approval year: 2023 (chronic weight management); December 2024 (moderate-to-severe obstructive sleep apnea in adults with obesity)
• FDA-approved indication: Chronic weight management in adults with BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbid condition; also approved for moderate-to-severe obstructive sleep apnea in adults with obesity
• Drug class: Dual GIP and GLP-1 receptor agonist (first-in-class)
• Manufacturer: Eli Lilly
• Typical monthly cost without insurance: $1,050–$1,300
• Primary clinical trial: SURMOUNT-1 (Jastreboff et al., NEJM 2022) — 22.5% mean weight reduction at the highest dose over 72 weeks

What Zepbound is and what it is FDA-approved to treat

Zepbound is the first-in-class dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors — a mechanism that produces greater average weight loss in clinical trials than any single-receptor GLP-1 agonist. Eli Lilly manufactures it as a weekly subcutaneous injection, starting at 2.5 mg and titrating up to a maximum of 15 mg. Without insurance, it runs approximately $1,050–$1,300 per month, making sustained out-of-pocket use financially out of reach for most patients.

The FDA-approved weight-management indication covers adults with a BMI of 30 kg/m² or above, or adults with a BMI of 27 kg/m² or above who have at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or dyslipidemia. If you are being prescribed Zepbound specifically for one of those reasons, your appeal is an on-label appeal — the strongest possible position. The December 2024 OSA approval is notable because it potentially unlocks coverage pathways that are entirely separate from obesity medication formulary rules, including in some plans that categorically exclude weight-loss drugs.

If your physician is prescribing Zepbound for a condition not listed above — for example, for polycystic ovary syndrome alone, or for cardiovascular risk reduction without an obesity or OSA diagnosis — your appeal is technically off-label and will face a higher bar. Being honest about this with your doctor upfront helps you build the most realistic strategy.

How major US insurers decide whether to cover Zepbound

Most large US insurers cover Zepbound in 2024–2025, but with strict prior authorization criteria that trip up many patients before they even reach the appeals stage. UnitedHealthcare covers it with BMI plus comorbidity criteria and requires six months of documented lifestyle program participation. Aetna lists Zepbound alongside Wegovy and Saxenda but typically requires a prior trial of phentermine (a step-therapy requirement). Cigna requires structured weight-loss program documentation and enforces a 5% weight-loss threshold at 12 weeks for reauthorization. Anthem/Elevance Health covers it under medical necessity criteria. BCBS state plans have added Zepbound to their formularies in 2024, though coverage terms vary significantly by state. Kaiser Permanente shows regional variation and in some markets actually prefers Zepbound over Wegovy for tirzepatide-naive patients.

Several categories of plans are more likely to exclude Zepbound entirely. Many employer-sponsored plans have anti-obesity medication carve-outs — blanket exclusions that have nothing to do with your medical profile. Most Medicare Part D plans still cannot cover weight-loss medications under the federal exclusion in Section 1860D-2(e)(2)(A) of the Social Security Act, though the new sleep apnea indication may create a separate coverage pathway for some Medicare beneficiaries. Some state Medicaid programs also exclude anti-obesity drugs depending on their formulary decisions.

The most common reasons insurers deny Zepbound

Insurers most commonly deny Zepbound for one of seven specific reasons, and knowing which one applies to you determines how you fight back.

• Your documented BMI does not meet the insurer's threshold (most require ≥ 30, or ≥ 27 with a qualifying comorbidity)
• Your comorbidity is not on the insurer's recognized list — PCOS, osteoarthritis, and depression are frequently excluded even though they are obesity-related
• Your prior authorization request lacks documentation of a structured lifestyle modification program
• You have not completed required step therapy — many plans require a prior trial of phentermine, Saxenda, or Wegovy before Zepbound is approved
• Your plan has an employer-level anti-obesity medication carve-out, meaning no weight-loss drug is covered regardless of medical need
• At reauthorization (typically 12 weeks in), you did not demonstrate at least 5% weight loss
• Your insurer has a formulary preference for Wegovy due to rebate agreements and is denying Zepbound on that basis

The denial letter you received should specify which criterion triggered the denial. If it is vague, you have the right to request the specific clinical criteria used — and under ERISA Section 503 and ACA Section 2719, your insurer is legally required to provide them.

How to address each denial reason

BMI threshold or comorbidity not met: Ask your physician to provide the most recent documented BMI measurement from your medical record, along with a complete problem list. If your BMI is 27–29.9, the comorbidity documentation is your entire case — your physician's letter should name the specific condition, its ICD-10 code, and the clinical basis for calling it weight-related.

Comorbidity not on insurer's recognized list: PCOS and osteoarthritis are the two conditions most often excluded from insurer comorbidity lists despite clinical evidence linking them to excess body weight. Your physician should reference the AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity (Garvey et al., Endocr Pract. 2023) to argue that the insurer's list is narrower than the clinical standard of care.

Lifestyle program documentation missing: Gather any records from a registered dietitian, a physician-supervised diet program, a medically documented caloric restriction program, or a structured exercise intervention. Even well-documented primary care counseling sessions can count. The records should show duration, type of intervention, and lack of sufficient response.

Step therapy not completed: If you have not tried the required predecessor drug, ask your physician whether a clinical exemption applies — for example, if phentermine is contraindicated given your cardiovascular history, or if you have already failed a GLP-1 monotherapy like Wegovy. Document that exception explicitly. If you have completed step therapy, include a clear timeline with dates, doses, and outcomes.

Plan-level anti-obesity carve-out: This is the hardest denial to overturn through standard appeals. Your first step is confirming whether the exclusion is truly blanket by requesting the Summary Plan Description. If it is, escalate to your HR department — many employers have added Zepbound coverage recently due to cost modeling showing downstream healthcare savings, and employer pressure sometimes changes plan design faster than appeals do. If you have a sleep apnea diagnosis, the OSA indication may allow coverage under a different benefit category entirely.

Reauthorization denial for insufficient weight loss: Cigna and other insurers typically require 5% weight loss by 12 weeks. If you are close but not quite there, your physician can provide clinical context — for example, if you were still on a lower titration dose, or if concurrent medications slowed response. The SURMOUNT-1 trial data showed weight loss continued to increase through 72 weeks, which supports the argument that 12 weeks is an inadequate measurement window for patients still titrating.

Formulary preference for Wegovy: If your insurer is denying Zepbound specifically in favor of Wegovy, and your physician has a clinical reason to prefer tirzepatide's dual-receptor mechanism — particularly if you have type 2 diabetes, as supported by SURMOUNT-2 (Garvey et al., Lancet 2023) — document that clinical rationale explicitly. Formulary preference denials can be overridden when a physician demonstrates that the preferred drug is clinically inferior for a specific patient.

How Zepbound differs from other GLP-1 medications

Zepbound produces the largest average weight loss of any currently approved anti-obesity medication. The SURMOUNT-1 trial showed a mean 22.5% body weight reduction at the highest dose over 72 weeks — substantially higher than the approximately 15% seen with semaglutide 2.4 mg (Wegovy) in the STEP 1 trial (Wilding et al., NEJM 2021). This difference matters clinically and matters in your appeal.

The key distinction from Wegovy and Ozempic is mechanism: Zepbound is a dual GIP and GLP-1 receptor agonist, while Wegovy and Ozempic are GLP-1 receptor agonists only. Ozempic (semaglutide 1 mg) is FDA-approved for type 2 diabetes — not weight loss — so using Ozempic for weight management is off-label. Wegovy (semaglutide 2.4 mg) is FDA-approved for weight management, as is Zepbound. Mounjaro (tirzepatide) contains the same active ingredient as Zepbound but is FDA-approved only for type 2 diabetes, not weight management — meaning a patient who takes Mounjaro for weight loss is in an off-label situation regardless of BMI.

If you previously failed or had inadequate response to Wegovy or another GLP-1 monotherapy, that clinical history is one of the strongest factors in a Zepbound appeal, because it directly addresses why the insurer's preferred alternative is insufficient for you specifically.

Federal and state laws that protect your right to appeal

You have a federally protected right to appeal this denial. For employer-sponsored plans governed by ERISA, Section 503 (implementing regulations at 29 CFR 2560.503-1) requires your plan to provide a full and fair review of any denied claim, deliver a written explanation of the denial in plain language, and allow you to submit additional evidence on appeal. Plans must decide your internal appeal within 60 days for non-urgent matters.

For plans purchased through the ACA marketplace, Section 2719 (45 CFR 147.136) guarantees you both an internal appeal and, if that fails, an independent external review by a reviewer the insurer does not control. This external review is one of the most powerful tools available — insurers overturn a meaningful percentage of denials at the external review stage.

ACA Section 1557 prohibits discrimination on the basis of disability and sex in health programs receiving federal funding. Obesity is increasingly recognized as a chronic disease, and some patients have successfully invoked Section 1557 in appeals where blanket anti-obesity medication exclusions appear to single out a specific patient population without clinical justification.

State law may add further protections. A growing number of states have passed parity laws requiring commercial insurers to cover obesity medications under the same standards as other chronic-disease medications. Check your state's insurance commissioner website or ask your physician's office for local guidance.

What a strong appeal letter contains

A strong Zepbound appeal letter opens with the FDA approval fact — that Zepbound received FDA approval in 2023 for chronic weight management and in December 2024 for obstructive sleep apnea — because it immediately establishes this is an on-label, evidence-backed prescription, not an experimental request. Every factual claim your physician makes should be tied to a specific document.

The letter should include:

• Patient's documented BMI with date of measurement and the ICD-10 code for obesity or overweight
• Names and ICD-10 codes of all qualifying comorbidities, with dates of diagnosis
• Summary of prior weight-loss interventions, including dates, duration, and outcomes (lifestyle programs, prior pharmacotherapy)
• If step therapy applies: documentation of each required prior drug trial, with dose, duration, and response
• Clinical trial citation: SURMOUNT-1 (Jastreboff et al., NEJM 2022), noting the 22.5% mean weight reduction, to establish the drug's evidence base
• If sleep apnea applies: SURMOUNT-OSA (Malhotra et al., NEJM 2024) and reference to the American Academy of Sleep Medicine Position Statement on Pharmacotherapy for OSA (2025)
• Reference to AACE/ACE Clinical Practice Guidelines (Garvey et al., Endocr Pract. 2023) establishing Zepbound as consistent with the standard of care
• A closing paragraph citing the applicable statute (ERISA Section 503, ACA Section 2719, or both) and requesting written denial criteria if not already provided

The letter should be written by your prescribing physician or specialist, on letterhead, and submitted with supporting records as attachments. Vague letters that simply say "medically necessary" without evidence almost always fail.

Timeline: what happens after you submit your appeal

Your insurer must acknowledge your internal appeal within a few business days of receipt. For standard (non-urgent) appeals under ERISA plans, the plan has up to 60 days to issue a decision. For ACA marketplace plans, the timeline is 30 days for pre-service appeals. Keep a dated record of everything you submit and request confirmation of receipt.

If the internal appeal is denied, you have the right to request an independent external review. For ACA plans and many ERISA plans using voluntary external review programs, you submit your request to your state insurance commissioner or to a federally designated Independent Review Organization (IRO). External reviewers are bound by clinical evidence standards, not the insurer's formulary preferences, which is why patients who reach this stage with strong clinical documentation win a meaningful portion of the time.

While your appeal is pending, ask your physician about Eli Lilly's savings programs. Lilly currently offers a savings card that can reduce out-of-pocket costs for commercially insured patients, and there is a separate program for uninsured patients. These do not replace coverage but can bridge the gap during the appeals process.

Frequently asked questions about appealing a Zepbound denial

Does the new sleep apnea FDA approval help if my plan excludes weight-loss drugs?

The December 2024 FDA approval for obstructive sleep apnea may unlock a separate coverage pathway even if your plan has a blanket anti-obesity medication exclusion. Because the OSA indication is a distinct disease approval, not a weight-management approval, some plans that categorically exclude "weight-loss drugs" may cover Zepbound when it is prescribed specifically to treat documented moderate-to-severe OSA in an adult with obesity. Your physician should frame the prescription under the OSA indication, citing SURMOUNT-OSA (Malhotra et al., NEJM 2024), and submit a separate prior authorization request using the OSA diagnosis codes rather than obesity codes.

My plan says I need to try phentermine first — can I skip that step?

Step-therapy requirements can be waived when there is a clinical reason the required drug is contraindicated or inappropriate. Phentermine is a sympathomimetic stimulant with cardiovascular contraindications, including uncontrolled hypertension, a history of heart disease, or hyperthyroidism. If any of these apply, your physician can document a step-therapy exemption. Several states have also passed step-therapy override laws that require plans to grant an exception when a physician certifies that the required drug is clinically inferior for a specific patient — check whether your state has one.

Can I appeal a Medicare denial for Zepbound?

Most Medicare Part D plans are currently prohibited from covering Zepbound for weight management under the federal weight-loss drug exclusion in Section 1860D-2(e)(2)(A) of the Social Security Act. However, if you have a documented diagnosis of moderate-to-severe obstructive sleep apnea and your physician prescribes Zepbound under the December 2024 OSA indication, Medicare coverage may be available through a different mechanism. This is a rapidly evolving area, and you should ask your physician and your Part D plan specifically about the OSA indication.

What if my employer's plan just excludes all anti-obesity medications entirely?

An employer-level anti-obesity medication carve-out is a plan design decision that cannot typically be overturned through the standard medical-necessity appeals process. Your most effective options are: confirming the exclusion applies to all anti-obesity drugs (not just Zepbound specifically), raising the issue with your HR or benefits department and citing the downstream healthcare costs of untreated obesity, and — if you also have an OSA diagnosis — exploring whether the sleep apnea indication bypasses the anti-obesity carve-out. If you believe the exclusion discriminates against you on the basis of a disability, an attorney familiar with ACA Section 1557 can evaluate whether a challenge is viable.

What is the 5% weight-loss requirement and what do I do if I don't meet it?

The 5% weight-loss benchmark at 12 weeks is a reauthorization criterion used by Cigna and some other insurers to determine whether you are responding to treatment. If you have not reached 5% by that checkpoint, your physician should document your titration history — patients who are still escalating from lower doses at 12 weeks have not yet reached therapeutic dosing, and the SURMOUNT-1 trial demonstrated that weight loss continued to accumulate through 72 weeks. Your physician can argue that premature discontinuation based on a 12-week snapshot is inconsistent with the clinical evidence and with the AACE/ACE guidelines.

Get a physician-ready appeal letter in 30 minutes

Writing an effective appeal letter takes time your physician's office often does not have. PriorAuthAppeal.com offers a service ($59, with a money-back guarantee if your physician declines to sign) that generates a physician-ready, fully cited appeal letter specific to Zepbound within about 30 minutes — drawing on the clinical trials, FDA approval data, and denial-specific arguments covered in this guide. That said, everything you need to write your own letter is already here. Whether you use a service or do it yourself, the single most important thing is specificity: exact BMI numbers, exact trial names, exact statute citations, and a physician's signature attached to supporting records. A well-built appeal gives you a real shot at reversal, even on the first try.